We are live on ! Find out more
GCM

Geneva Capital Management Portfolio holdings

AUM $4.36B
1-Year Est. Return 17.81%
This Fund
S&P 500
This Quarter Est. Return
+13.52%
1 Year Est. Return
+17.81%
3 Year Est. Return
+59.44%
5 Year Est. Return
+75.65%
10 Year Est. Return
AUM
$5.3B
AUM Growth
+$550M
Cap. Flow
-$8.16M
Cap. Flow %
-0.15%
Top 10 Hldgs %
26.27%
Holding
128
New
3
Increased
40
Reduced
84
Closed
1

Top Buys

Rank Stock Value
1
CERT icon
Certara
CERT
+$12.6M
2
GO icon
Grocery Outlet
GO
+$12.5M
3
EXPO icon
Exponent
EXPO
+$12M
4
DGII icon
Digi International
DGII
+$11.5M
5
ODFL icon
Old Dominion Freight Line
ODFL
+$10.3M

Sector Composition

Rank Sector Weight
1 Technology 36.37%
2 Industrials 27.95%
3 Healthcare 12.1%
4 Consumer Discretionary 8.29%
5 Financials 4.96%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
GMED icon
26
Globus Medical
GMED
$11.2B
$75.8M 1.43%
1,421,899
-325
-0% -$15.8K
DV icon
27
DoubleVerify
DV
$2.03B
$69.7M 1.32%
1,895,540
+328,431
+21% +$10.2M
MRTN icon
28
Marten Transport
MRTN
$1.22B
$69.6M 1.31%
3,315,946
-21,122
-0.6% -$403K
CERT icon
29
Certara
CERT
$1.25B
$67.3M 1.27%
3,824,850
+860,763
+29% +$12.6M
PRFT
30
DELISTED
Perficient Inc
PRFT
$62.7M 1.18%
952,399
+2,825
+0.3% +$174K
BL icon
31
BlackLine
BL
$1.72B
$57.8M 1.09%
925,741
-6,257
-0.7% -$354K
HQY icon
32
HealthEquity
HQY
$8.75B
$57.7M 1.09%
870,735
-5,613
-0.6% -$389K
BFAM icon
33
Bright Horizons
BFAM
$3.86B
$55.5M 1.05%
589,331
-9,618
-2% -$820K
AGYS icon
34
Agilysys
AGYS
$3.06B
$52.6M 0.99%
620,361
+102,939
+20% +$8.36M
ENV
35
DELISTED
ENVESTNET, INC.
ENV
$52.2M 0.99%
1,054,310
-21,496
-2% -$879K
AXON
36
Axon Enterprise
AXON
$46.4B
$52.1M 0.98%
201,838
-1,281
-0.6% -$289K
WDFC icon
37
WD-40
WDFC
$3.15B
$51.9M 0.98%
217,281
-180
-0.1% -$40.2K
CPRT icon
38
Copart
CPRT
$27.5B
$51.7M 0.98%
1,054,487
-120,261
-10% -$5.68M
LMAT icon
39
LeMaitre Vascular
LMAT
$1.86B
$51.4M 0.97%
904,724
-1,904
-0.2% -$99.7K
NVEE
40
DELISTED
NV5 Global
NVEE
$49.4M 0.93%
1,778,052
+2,828
+0.2% +$71.8K
DORM icon
41
Dorman Products
DORM
$4.18B
$49M 0.92%
586,952
-373
-0.1% -$27.9K
DCI icon
42
Donaldson
DCI
$11.4B
$47.6M 0.9%
728,490
-1,870
-0.3% -$114K
SPXC icon
43
SPX Corp
SPXC
$10.8B
$47.1M 0.89%
465,807
+853
+0.2% +$73.8K
ORLY icon
44
O'Reilly Automotive
ORLY
$76.3B
$45.6M 0.86%
719,910
-25,890
-3% -$1.64M
INTU icon
45
Intuit
INTU
$89B
$45.3M 0.85%
72,405
-2,613
-3% -$1.44M
NEOG icon
46
Neogen
NEOG
$2.5B
$43M 0.81%
2,138,629
+490,907
+30% +$8.31M
APH icon
47
Amphenol
APH
$209B
$41.3M 0.78%
832,794
-30,342
-4% -$1.34M
CSGP icon
48
CoStar Group
CSGP
$12.3B
$40.1M 0.76%
459,017
-2,788
-0.6% -$226K
IIIV icon
49
i3 Verticals
IIIV
$342M
$40M 0.75%
1,887,826
+5,519
+0.3% +$111K
AX icon
50
Axos Financial
AX
$5.68B
$39.8M 0.75%
728,143
+507
+0.1% +$21.2K

Similar funds

Geneva Capital Management's Q4 2023 Portfolio in Review

As of Q4 2023, Geneva Capital Management held 128 positions worth $5.3B, up 12% from $4.75B the previous quarter. Its ten largest holdings account for 26% of the portfolio.

Trading was light in Q4 2023: portfolio turnover was 3.1%. Geneva Capital Management opened 3 new positions and exited 1, leaving the 128-position portfolio largely intact.

By sector, the portfolio is most concentrated in Technology at 36% of assets, up from 36% a quarter earlier, followed by Industrials and Healthcare.

  • Geneva Capital Management's largest Q4 2023 buy was Old Dominion Freight Line: 52,106 shares worth $10.6M.
  • Geneva Capital Management added most to Certara in Q4 2023, an estimated $12.6M increase.
  • Geneva Capital Management's biggest Q4 2023 reduction was Fair Isaac, cutting an estimated $76.8M.
  • Geneva Capital Management fully exited Avid Bioservices, Inc. Common Stock in Q4 2023, selling an estimated $21.3M.
  • Geneva Capital Management's ten largest holdings make up 26% of its $5.3B portfolio in Q4 2023.
  • Geneva Capital Management opened 3 new positions and closed 1 in Q4 2023.
  • Geneva Capital Management's portfolio value rose 12% quarter-over-quarter to $5.3B.

Based on Geneva Capital Management's 13F filing for Q4 2023, filed 7 Feb 2024.